Abbott dives into cancer diagnostics with $23B buyout of Exact Sciences

Abbott announced a $23 billion acquisition of Exact Sciences, the developer of Cologuard and blood-based cancer screening tests. The deal marks the largest diagnostics acquisition to date and significantly expands Abbott's oncology diagnostic portfolio, combining Exact Sciences' colorectal and multi-cancer detection platforms with Abbott's existing diagnostic infrastructure and distribution capabilities.